Jornal Brasileiro de Patologia e Medicina Laboratorial (Feb 2014)

Thalidomide promotes leukocytosis in mice inoculated with 4T1 mammary carcinoma

  • Diego Carlos dos Reis,
  • Cristina Maria de Souza,
  • Liliane Cunha Campos,
  • Ana Cândida Araújo e Silva,
  • Miriam Teresa Paz Lopes,
  • Geovanni Dantas Cassali,
  • Enio Ferreira

DOI
https://doi.org/10.1590/S1676-24442014000100009
Journal volume & issue
Vol. 50, no. 1
pp. 64 – 66

Abstract

Read online

The aim of this study was to evaluate the therapy effect of thalidomide in the 4T1 murine mammary carcinoma. 4T1 cell suspension was injected into the posterior left flank of all animals to obtain solid tumors. Five days after inoculation, the treatment group was orally administered 150 mg/kg of thalidomide for seven days. Tumors were measured every 48 hours until the end of treatment. Whole blood was collected for hematology analysis. Our results suggest that thalidomide therapy increase the number of circulating leukocytes in the 4T1 murine mammary carcinoma, and this response is accompanied by a decrease in tumor growth.

Keywords